SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI

Neoplasia (United States)

Volumn 19, Issue 1, 2017, Pages 1-7

  Deng, Lei ^a   Stafford, Jason H ^a   Liu, Shie Chau ^a   Chernikova, Sophia B ^a   Merchant, Milton ^b   Recht, Lawrence ^b   Martin Brown, J ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B 20; BEVACIZUMAB; CD68 ANTIGEN; FERUMOXYTOL; OLAPTESED PEGOL; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APTAMER; BIOLOGICAL MARKER; NOX-A12; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY DENSITY; CELL INFILTRATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MACROPHAGE MIGRATION INHIBITION; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR HYPOXIA; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; MACROPHAGE; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BEVACIZUMAB; BIOMARKERS; CELL LINE, TUMOR; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HUMANS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016054459     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.11.010     Document Type: Article

References (33)

1. [1] Gilbert, MR, Dignam, JJ, Armstrong, TS, Wefel, JS, Blumenthal, DT, Vogelbaum, MA, Colman, H, Chakravarti, A, Pugh, S, Won, M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370 (2014), 699–708.
2. [2] Chinot, OL, Wick, W, Mason, W, Henriksson, R, Saran, F, Nishikawa, R, Carpentier, AF, Hoang-Xuan, K, Kavan, P, Cernea, D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370 (2014), 709–722.
3. [3] Omuro, A, DeAngelis, LM, Glioblastoma and other malignant gliomas: a clinical review. JAMA 310 (2013), 1842–1850.
4. [4] Ferrara, N, Hillan, KJ, Gerber, HP, Novotny, W, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004), 391–400.
5. [5] Ferrara, N, Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 17 (2010), 219–224.
6. [6] De Palma, M, Lewis, CE, Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23 (2013), 277–286.
7. [7] Bergers, G, Hanahan, D, Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008), 592–603.
8. [8] Franklin, RA, Liao, W, Sarkar, A, Kim, MV, Bivona, MR, Liu, K, Pamer, EG, Li, MO, The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925.
9. [9] Qian, BZ, Pollard, JW, Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51.
10. [10] Kioi, M, Vogel, H, Schultz, G, Hoffman, RM, Harsh, GR, Brown, JM, Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120 (2010), 694–705.
11. [11] Liu, SC, Alomran, R, Chernikova, SB, Lartey, F, Stafford, J, Jang, T, Merchant, M, Zboralski, D, Zollner, S, Kruschinski, A, et al. Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol 16 (2014), 21–28.
12. [12] Ahn, GO, Brown, JM, Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow–derived myelomonocytic cells. Cancer Cell 13 (2008), 193–205.
13. [13] Daldrup-Link, HE, Golovko, D, Ruffell, B, Denardo, DG, Castaneda, R, Ansari, C, Rao, J, Tikhomirov, GA, Wendland, MF, Corot, C, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17 (2011), 5695–5704.
14. [14] Yang, R, Sarkar, S, Korchinski, DJ, Wu, Y, Yong, VW, Dunn, JF, MRI monitoring of monocytes to detect immune stimulating treatment response in brain tumor. Neuro Oncol, 2016 [Published online: August 29, 2016].
15. [15] Carlson, BL, Pokorny, JL, Schroeder, MA, Sarkaria, JN, Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol, 2011 [Chapter 14, Unit 14 16].
16. [16] Huveldt, D, Lewis-Tuffin, LJ, Carlson, BL, Schroeder, MA, Rodriguez, F, Giannini, C, Galanis, E, Sarkaria, JN, Anastasiadis, PZ, Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One, 8, 2013, e56505.
17. [17] Liang, WC, Wu, X, Peale, FV, Lee, CV, Meng, YG, Gutierrez, J, Fu, L, Malik, AK, Gerber, HP, Ferrara, N, et al. Cross-species vascular endothelial growth factor (VEGF)–blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281 (2006), 951–961.
18. [18] Raina, S, Honer, M, Kramer, SD, Liu, Y, Wang, X, Segerer, S, Wuthrich, RP, Serra, AL, Anti-VEGF antibody treatment accelerates polycystic kidney disease. Am J Physiol Renal Physiol 301 (2011), F773–F783.
19. [19] Martinez, RLMC, Naranjo, JD, A pretest for choosing between logrank and wilcoxon tests in the two-sample problem. Metron LXVIII (2010), 111–125.
20. [20] Achyut, BR, Shankar, A, Iskander, AS, Ara, R, Angara, K, Zeng, P, Knight, RA, Scicli, AG, Arbab, AS, Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks. Cancer Lett 369 (2015), 416–426.
21. [21] Xu, L, Duda, DG, di Tomaso, E, Ancukiewicz, M, Chung, DC, Lauwers, GY, Samuel, R, Shellito, P, Czito, BG, Lin, PC, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69 (2009), 7905–7910.
22. [22] Galdiero, MR, Bonavita, E, Barajon, I, Garlanda, C, Mantovani, A, Jaillon, S, Tumor associated macrophages and neutrophils in cancer. Immunobiology 218 (2013), 1402–1410.
23. [23] Welford, AF, Biziato, D, Coffelt, SB, Nucera, S, Fisher, M, Pucci, F, Di Serio, C, Naldini, L, De Palma, M, Tozer, GM, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121 (2011), 1969–1973.
24. [24] Daly, C, Eichten, A, Castanaro, C, Pasnikowski, E, Adler, A, Lalani, AS, Papadopoulos, N, Kyle, AH, Minchinton, AI, Yancopoulos, GD, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73 (2013), 108–118.
25. [25] Zhang, W, Zhu, XD, Sun, HC, Xiong, YQ, Zhuang, PY, Xu, HX, Kong, LQ, Wang, L, Wu, WZ, Tang, ZY, Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16 (2010), 3420–3430.
26. [26] Hughes, R, Qian, BZ, Rowan, C, Muthana, M, Keklikoglou, I, Olson, OC, Tazzyman, S, Danson, S, Addison, C, Clemons, M, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 75 (2015), 3479–3491.
27. [27] Lu-Emerson, C, Snuderl, M, Kirkpatrick, ND, Goveia, J, Davidson, C, Huang, Y, Riedemann, L, Taylor, J, Ivy, P, Duda, DG, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol 15 (2013), 1079–1087.
28. [28] Karin, N, The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol 88 (2010), 463–473.
29. [29] Du, R, Lu, KV, Petritsch, C, Liu, P, Ganss, R, Passegue, E, Song, H, Vandenberg, S, Johnson, RS, Werb, Z, et al. HIF1alpha induces the recruitment of bone marrow–derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 (2008), 206–220.
30. [30] Miao, Z, Luker, KE, Summers, BC, Berahovich, R, Bhojani, MS, Rehemtulla, A, Kleer, CG, Essner, JJ, Nasevicius, A, Luker, GD, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 104 (2007), 15735–15740.
31. [31] Kryczek, I, Lange, A, Mottram, P, Alvarez, X, Cheng, P, Hogan, M, Moons, L, Wei, S, Zou, L, Machelon, V, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65 (2005), 465–472.
32. [32] Tabatabai, G, Frank, B, Mohle, R, Weller, M, Wick, W, Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha–mediated induction of CXCL12. Brain 129 (2006), 2426–2435.
33. [33] Schwenk, MH, Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 30 (2010), 70–79.